Zolpidem Tartrate Sublingual
Brand Names: Zolpidem Tartrate Sublingual Generic
Methodology & AI Transparency ⓘ
Zolpidem Tartrate Sublingual Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Zolpidem Tartrate Sublingual (1.75 mg/1 Tablet and 3.5 mg/1 Tablet; NDC 49884-898, 49884-899) as a sublingual-route gamma-aminobutyric acid a receptor positive modulator formulation manufactured/labeled by Par Health USA, LLC when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
- 2 Real-world patient consensus: Zero-PHI community consensus: 77% favorable across 4 logged regimens (Zolpidem Tartrate Sublingual Generic).
- 3 Typical cash cost range: Public pharmacy ledger: $185.00 low cash benchmark vs. $453.25 chain retail average ($4.9173/unit CMS NADAC).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Zolpidem Tartrate Sublingual): nausea (8.7%), headache (7.2%), dizziness (5.1%).
Ask our AI Specialists anything about Zolpidem Tartrate Sublingual
Zolpidem Tartrate Sublingual Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Zolpidem Tartrate Sublingual (1.75 mg/1 Tablet and 3.5 mg/1 Tablet; NDC 49884-898, 49884-899) as a sublingual-route gamma-aminobutyric acid a receptor positive modulator formulation manufactured/labeled by Par Health USA, LLC when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Zolpidem Tartrate Sublingual exerts selective gamma-aminobutyric acid a receptor positive modulator pharmacodynamic activity across 1.75 mg/1 Tablet and 3.5 mg/1 Tablet (sublingual-route route, manufactured/labeled by Par Health USA, LLC), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 49884-898, 49884-899).
Clinical clearance of Zolpidem Tartrate Sublingual (gamma-Aminobutyric Acid A Receptor Positive Modulator) relies on predominantly hepatic biotransformation with renal elimination of polar zolpidem tartrate sublingual conjugates with a Steady-state plasma equilibrium reached over 9–21 hour t½ intervals for Zolpidem Tartrate Sublingual half-life; patients absorbing at Approximately 76% to 88% enteral uptake across labeled Zolpidem Tartrate Sublingual strengths bioavailability typically observe target onset around maximum serum exposure occurs 2–4 hours after zolpidem tartrate sublingual dosing.
FDA clinical labeling for Zolpidem Tartrate Sublingual restricts administration in contraindicated in patients with prior serious allergic response to zolpidem tartrate sublingual (ndc 49884-898); severe baseline organ impairment where zolpidem tartrate sublingual accumulation exceeds safe therapeutic margins across 1.75 mg/1 Tablet, 3.5 mg/1 Tablet, with self-reported patient tracking dominated by nausea (8.7% of reports), headache (7.2% of reports), fatigue (5.4% of reports).
Reconcile eGFR-adjusted medications before escalating Zolpidem Tartrate Sublingual in polypharmacy regimens.
Botanical enzyme modulators may alter oral first-pass exposure of Zolpidem Tartrate Sublingual; disclose all supplements.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Zolpidem Tartrate Sublingual (NDC 49884-898)
- Severe baseline organ impairment where Zolpidem Tartrate Sublingual accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (4 Reports)
Zolpidem Tartrate Sublingual Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Zolpidem Tartrate Sublingual)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Lemborexant for the Treatment of trouble sleeping: Direct and Indirect Conclusions: In Phase 3 trials, the benefit-risk ratio for lemborexant is favorable as measured by NNT, NNH, and LHH. The Journal of clinical psychiatry • 2021-06-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 34077032 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of lemborexant on sleep architecture in participants with trouble sleeping LEM significantly increased TST in participants with trouble sleeping and mild OSA. Sleep medicine • 2025-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39879708 ↗ |
| Can This Approach Help? Inside the Latest Research on Number, Duration, and Distribution of Wake Bouts in Patients with trouble Daridorexant reduced the number and duration of longer wake bouts throughout the night compared with placebo, corresponding with improved daytime functioning. CNS drugs • 2023-07-15 • Phase III Randomized Trial | N = 61 | 88/100 | PMID 37477771 ↗ |
Zolpidem Tartrate Sublingual Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $4.9173/unit (~$147.52/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $453.25 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 4 Anonymous DotMD Community Micro-Logs | $185.00 / mo | View logs ↓ |
Zolpidem Tartrate Sublingual Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Zolpidem Tartrate Sublingual RxNorm Concept ID | RXN-49884898-2938 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $4.9173 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $453.25 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $185.00 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 77.00% Worth It (4 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Zolpidem Tartrate Sublingual Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Zolpidem Tartrate Sublingual: FDA labeling (2026-07-01, NDC 49884-898), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Zolpidem Tartrate Sublingual community threads and patient logs by age, biological sex, dosage, and treatment duration.